Page 5 - Renal Dysfunction News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Bristol Myers Squibb Presents New Research at ASCO and EHA 2021 Featuring Novel Approaches and Demonstrating Significant Progress to Improve Survival in Cancer and Blood Disorders First Phase 3 data from the RELATIVITY-047 trial highlight clinical benefit of LAG-3 blocking antibody relatlimab the company’s third distinct checkpoint inhibitor in combination with nivolumab for patients with previously untreated unresectable or metastatic melanoma First disclosure of results from CheckMate -648 demonstrate Opdivo plus Yervoy and Opdivo plus chemotherapy’s potential to address unmet needs in ...

Recommendation based on positive results from the Phase 3 CheckMate -743 trial, in which Opdivo plus Yervoy demonstrated significantly superior overall survival vs. standard-of-care chemotherapy CheckMate -743 represents the first Phase 3 trial to show benefit with immunotherapy in previously untreated malignant pleural mesothelioma If approved, Opdivo plus Yervoy will be the first new treatment option authorized … Recommendation based on positive results from the Phase 3 CheckMate -743 trial, in which Opdivo plus Yervoy demonstrated significantly superior overall survival vs. standa...

Two Opdivo -based therapies are now authorized for first-line treatment of patients with advanced renal cell carcinoma in the European Union: Opdivo plus Yervoy in combination with Cabometyx Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo Cabometyx ® (cabozantinib) for the first-line treatment of adults with advanced renal cell carcinoma (RCC). The EC’s decision is based on results from the Phase 3 CheckMate -9ER trial, which demonstrated superior efficacy with Opdivo in combination with Cabometyx versus suni...

Nearly a quarter of patients who received Opdivo plus chemotherapy showed no evidence of cancer cells in tissue removed during surgery vs. 2.2% of patients who received chemotherapy alone Opdivo- based therapies have now demonstrated positive results in Phase 3 trials in earlier stages of four different types of cancer: non-small cell lung cancer, esophagealgastroesophageal junction cancer, bladder cancer and … Nearly a quarter of patients who received Opdivo plus chemotherapy showed no evidence of cancer cells in tissue removed during surgery vs. 2.2% of patients who received chemother...

1 1,2 as a standard of care for intermediate- or poor-risk patients 3 OPDIVO ® (nivolumab) 240 mg (injection for intravenous use) every two weeks or 480 mg every four weeks in combination with CABOMETYX ® (cabozantinib) 40 mg once daily tablets was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of patients with advanced renal cell carcinoma (RCC). 1 The approval is based on the Phase 3 CheckMate -9ER trial, which compared OPDIVO in combination with CABOMETYX (n=323) versus sunitinib (n=328) in patients with advanced RCC. 1 Thi...